United Cannabis Corp (OTCMKTS:CNAB) shares were up .25 cents a month before the 2016 election, and traded $3.00 when President Trump was elected. They were not the only stock that moved. It seemed retail investors bought every publicly traded cannabis stock they could find. Last week, CNAB rallied 40% to .85 cents and this tells the story of what the cannabis sector has done since late 2016.
Back in January, CNAB in tandem with BudCube Cultivation Systems, a subsidiary of Cherubim Interests Inc. (OTCMKTS: CHIT), announced the completion of construction and deployment of its first mobile testing and extraction laboratory.
United Cannabis Corp (OTCMKTS:CNAB) teamed with Jamaica-based Cannabis Research & Development initiating a pilot program in collaboration with the Rastafari Studies Centre for Cannabis Research, University of West Indies, Mona, to establish protocols for the development of Ital Standards which will be used as a guide for the processing, cultivation and consumption of cannabis.
CNAB will work in collaboration with the Rastafari Studies Centre to support the activities of the DHAPA Association in accord with their broader objective of establishing an infrastructure for licensed Rastafari farmers and trainees to participate in the Jamaican marijuana industry.
The Joint Venture’s initial task will be to document and verify the genetics of the Centre’s preliminary plantings, as well as provide guidance in the development of appropriate standards and training methods for future activities.
Subscribe below and we’ll keep you on top of what’s happening before $CNAB stock makes its next move.
“We at United Cannabis and Cannabinoid Research and Development are extremely happy with the attention to detail CHIT showed throughout this project. We feel the option to drop ship a lab pre-made to our specifications will deliver a competitive advantage to our affiliates and partners,” said CNAB CEO Earnest Blackmon.
“We are thrilled to execute and formally enter into this niche and position ourselves on firmer footing to take on more orders,” said CHIT CEO Patrick Johnson.
Also important to the progress is initiating clinical trials to study its proprietary Prana Bio Medicinals cannabinoid compounds. CBAB’s Prana Bio Medicinal products provide patients with a way to mix and match cannabinoids for their therapeutic purposes. Using a patent-pending technology, CNAB infuses cannabinoids, terpenes, and flavonoids without the use of any heat, solvents, or chemicals to produce 100% natural products. These products interact with the human endocannabinoid system, which has receptors throughout the body and is responsible for homeostasis. They are broken down into five color-coded categories and are available as capsules, sublinguals or topicals.
“We pride ourselves on not using any chemical solvents (i.e. nButane, C02, Ethanol, Hexane) in our extraction process,” states United Cannabis CTO Tony Verzura. “We utilize our patent-pending infusion process that extracts phytocannabinoids, terpenes, and flavonoids from raw flower material without the use of any heat. Heat ‘activates’ compounds and creates the hypnotic and euphoric feeling generally experienced with THC when paired with certain terpene profiles.
“We have systematically created a wide variety of both raw and ‘active’ categories, delivery methods, and doses that makes it easy for educated patients, practitioners, or researchers to target the Endocannabinoid system. Our P1 thru P5 categories systematically classify chemotypes of cultivars that express different ratios of THC, CBD, and terpene profiles. We are the only company in the world providing both raw and active ingredients in a 100% plant-based hypoallergenic formula with multiple delivery methods ranging from 1 mg to 50 mg doses.
“Additional to the products, we provide a complimentary program (A.C.T. Now) administered by professional practitioners to help patients personalize the medicine for their specific needs in a HIPAA compliant cloud-based Electronic Health Records software. The combination of our products currently being used in the biggest market in the United States serving thousands of patients, and our integrated approach to personalized patient care separates us from the competition.”
United Cannabis Corp (OTCMKTS:CNAB) long-term goal is to develop its Prana products into a line of approved pharmaceutical drugs that physicians can prescribe to their patients. In order to do so, CNAB must undertake extensive clinical trials designed to prove both the safety and efficacy of cannabinoid-based compounds given that only a handful of synthetic compounds have been approved by government regulatory bodies thus far. Know that we have another important cycle upcoming in the cannabis sector. The volatility will loom until we get a clear picture of the timing of federal regulation. We are keeping a close eye on this and are dedicated to writing about the sector each and every day. For continuing coverage on shares of $CNAB stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!